Previous 10 | Next 10 |
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company ...
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 PR Newswire MELBOURNE, Australia , Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biote...
Alterity Therapeutics (NASDAQ:ATHE) is rising following the publication of two preclinical studies showing the potential of ATH434 to treat Parkinsonian disorders. The company said that in the Parkinson's disease (PD) animal study, ATH434 treatment was started after gastrointestinal (GI)...
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases Colorectal impairment reversed in a preclinical model of Parkinson's Disease ATH434 presents a novel mechanism of action for the treatme...
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report PR Newswire Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. Expanded intellectual property ...
Diginex (NASDAQ:EQOS) +70% on its crypto exchange, EQONEX listing Polkadot token on its platform Bakkt Holdings (NYSE:BKKT) +67% after agreements with Fiserv, Mastercard Wallbox (NYSE:WBX) +56% Uber and Wallbox team up on the road to zero emissions Code Chain New Continent (NAS...
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program PR Newswire - Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expan...
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial PR Newswire MELBOURNE, Australia and SAN FRANCISCO ,...
Alterity has been granted notice of allowance by USPTO for a new group of iron chaperones that redistribute excess iron in neurodegenerative diseases. The Company’s iron chaperone technology has decent potential. The Company’s ATH434 is a promising candidate with ini...
GeoVax Labs (NASDAQ:GOVX) +75% presents COVID-19 vaccine data at the European Society of Medicine (ESMED) General Assembly Marin Software MRIN +25% integrates with Criteo's ecommerce media platform for advertising SunLink Health Systems (NYSE:SSY) +12%. The9 NCTY +9% ...
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
Alterity Therapeutics Limited Website:
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...